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Abstract: 
 
Background: In malaria-endemic populations, sickle cell trait (SCT) protects against both severe and non-severe 
malaria, but inconsistencies exist about protective effect of SCT on asymptomatic malarial parasitemia (AMP). 
Surprisingly, the effect of Hb-phenotypes on AMP has not been explored among blood donors in Nigeria or other 
malaria-endemic countries, where risks of AMP and transfusion transmitted malaria (TTM) are high. The objective of 
this study is to determine risk of AMP with respect to donor Hb-phenotypes (SCT versus HbAA), and elucidate 
clinical implications of AMP with respect to risk of TTM vis-à-vis the practice of transfusion medicine in Nigeria, and 
by implication other malaria-endemic tropical countries. 
Methodology: Analysis of 100 blood donors with AMP (cases) and 100 donors without AMP (controls) was 
performed. Frequencies of SCT and HbAA (determined by Hb electrophoresis) among cases and controls were 
compared by X2-test. Risks of AMP (detected by microscopy) with respect to Hb-phenotypes were expressed as 
Odds ratios (OR) by case-control logistic regression. 
Results: In comparison with blood donor without AMP (controls), donors with AMP had lower frequencies of SCT 
(12% vs 28%, p<0.05) with corresponding higher frequencies of HbAA (88% vs 72%, p<0.05). HbAA is associated 
with high risk of AMP (OR=2.91, 95%CI: 2.10-3.48, p=0.021), while SCT is associated low risk of AMP (OR=0.49, 
95%CI: 0.27-0.73, p=0.032). 
Conclusion: This finding shows that donor SCT is a surreptitious mitigator of the risk of AMP and TTM in the 
tropics. Therefore, patients who are selectively transfused with HbAA blood (e. g. neonates and sickle cell disease 
patients) could be at greater risks of TTM, and such patients need closer post transfusion monitoring. The risk of 
TTM calls for diligent post transfusion haemovigilance in Nigeria and other malaria endemic tropical countries in 
Africa 
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Abstrait: 
Contexte: Dans les populations d'endémie palustre, le trait drépanocytaire (SCT) protège à la fois contre le 
paludisme grave et non sévère, mais des incohérences existent quant à l'effet protecteur de la SCT sur la 
parasitémie asymptomatique du paludisme (AMP). De manière surprenante, l'effet des phénotypes Hb sur l'AMP n'a 
pas été exploré chez les donneurs de sang au Nigéria ou dans d'autres pays d'endémie palustre, où les risques de 
PMA et de paludisme transmis par transfusion (TTM) sont élevés. L'objectif de cette étude est de déterminer le 
risque d'AMP par rapport aux phénotypes Hb des donneurs (SCT versus HbAA), et d'élucider les implications 
cliniques de l'AMP en ce qui concerne le risque de TTM vis-à-vis de la pratique de la médecine transfusionnelle au 
Nigéria, et par implication d'autres pays tropicaux d'endémie palustre.                       
Méthodologie: Une analyse de 100 donneurs de sang avec AMP (cas) et 100 donneurs sans AMP (témoins) a été 
réalisée. Les fréquences de SCT et d'HbAA (déterminées par électrophorèse Hb) parmi les cas et les témoins ont été 
comparées par test X2. Les risques d'AMP (détectés par microscopie) par rapport aux phénotypes Hb ont été 
exprimés en odds ratios (OR) par régression logistique cas-témoins.                           
Résultats: En comparaison avec les donneurs de sang sans AMP (témoins), les donneurs avec AMP avaient des 
fréquences plus faibles de SCT (12% vs 28%, p<0,05) avec des fréquences plus élevées correspondantes d'HbAA 
(88% vs 72%, p<0,05). L'HbAA est associée à un risque élevé d'AMP (OR=2,91, IC à 95%: 2,10-3,48, p=0,021), 
tandis que la SCT est associée à un faible risque d'AMP (OR=0,49, ICà95%: 0,27-0,73, p=0,032).                             
Conclusion: Cette découverte montre que le donneur SCT est un atténuateur subreptice du risque d'AMP et de TTM 
dans les tropiques. Par conséquent, les patients qui sont sélectivement transfusés avec du sang HbAA (par 
exemple, les nouveau-nés et les patients atteints de drépanocytose) pourraient être plus à risque de TTM, et ces 
patients ont besoin d'une surveillance post-transfusionnelle plus étroite. Le risque de TTM appelle une 
hémovigilance post-transfusionnelle diligente au Nigéria et dans d'autres pays tropicaux endémiques du paludisme 
en Afrique 
Mots clés: donneurs de sang, trait drépanocytaire, parasitémie asymptomatique du paludisme, paludisme transmis 
par transfusion 
Introduction: donors is determined by pre-donation asses- 
sment of health status. A significant part of the 
assessment takes the form of verbal and/or 
questionnaire screening with reliance on 
answers to simple standard questions relating 
to general health, medical and social history, 
and simple general physical examination 
including the measurements of weight and 
blood pressure (8,9). Persons who are between 
the ages of 18 and 65 years, and have passed 
the pre-donation medical assessment with 
negative test results for HIV, hepatitis B and C 
viruses, and syphilis, with haemoglobin (Hb) 
levels of more than 13.5g/dl for males or 12.5 
g/dl for females are acceptable as donors (9). 
 Individuals with SCT are genetically 
heterozygous for the sickle β-globin gene and 
their red cells have the HbAS phenotype 
expressing both HbS (20-40%) and HbA (60-
80%) (1,10). The relative abundance of HbA 
prevents undue sickling and haemolysis under 
physiological conditions, hence the red cell life 
span is normal in SCT and affected individuals 
are symptomless, non-anaemic, and have 
normal life expectancy (10,11). Therefore, SCT 
does not in any way reduce the chances of 
passing routine pre-donations tests in affected 
individuals. Consequently, persons with SCT 
constitute a significant proportion of eligible 
blood donors in tropical African countries such 
as Nigeria, where up to one quarter (21-27%) 
 
 Haemoglobin S (HbS) is the best 
characterized human genetic polymorphism 
that is strongly associated with resistance to 
malaria (1). HbS is a structural variant of HbA 
that arose as a result of GAG > GTG base 
transition at codon-6 of the β-globin gene on 
chromosome-11, which corresponds to the 
substitution of glutamic acid (polar, hydrophilic 
amino acid) by valine (neutral, hydrophobic 
amino acid) at position-6 of the β-globin chain 
of the haemoglobin molecule (1). Conse- 
quently, HbS has less anionic potential, slower 
electrophoretic mobility and reduced deoxy- 
genated solubility that leads to polymerization, 
and red cell sickling (2). The sickle cell trait 
(SCT) refers to the heterozygous inheritance of 
the sickle β-gene (3). The SCT protects against 
severe falciparum malaria and confers survival 
advantage in populations living in malaria 
endemic countries (4). This is attained through 
the process of natural selection (5), mediated 
by the phenomenon of balanced polymorphism 
(6), and executed by immunological and bio- 
chemical mechanisms that protect individuals 
with SCT from malaria (7). Consequently, the 
prevalence of SCT in Nigeria and other tropical 
African countries is up to 25-30% in the 
general population (4).    
 In Nigeria, the eligibility of prospective 




of blood donors carry the SCT (12,13). 
Unfortunately, the SCT blood has certain dis- 
advantages; it is unsuitable for some blood 
banking procedures (e. g. leuco-filtration) and 
also inappropriate for transfusing certain vul- 
nerable patients (e. g. foetuses, neonates and 
sickle cell disease patients) (9). Therefore, the 
World Health Organization (WHO) does not 
consider SCT as a contraindication for blood 
donation as long as the blood is not subjected 
to leuco-depletion or used for transfusing 
foetuses (intra-uterine), neonates and patients 
with sickle cell disease (SCD) (9). 
comparison with randomly selected normal 
(AMP negative) control donors. In order to test 
our prediction and hypothesis, we conducted 
an analysis of the pattern and frequencies of 
haemoglobin phenotypes (SCT versus HbAA) 
among AMP positive blood donors in compari- 
son with randomly selected normal (AMP 
negative) control donors.    
 The aim of this study was two-folds; 
first, to determine the risk of AMP with respect 
to Hb phenotypes (SCT versus HbAA) of blood 
donors, and secondly, to elucidate and review 
the clinical implications of AMP positivity 
among blood donors with respect to the risk of 
TTM vis-à-vis the practice of transfusion medi- 
cine in Nigeria and, by implication, in other 
malaria endemic tropical African countries. 
 Extensive systematic and meta-analy- 
tical review revealed that various studies had 
consistently shown that SCT definitively pro- 
tects against both severe and uncomplicated 
malaria in the tropics, wherein SCT confers 
greater than 90% protection from severe mala- 
ria and up to 50% protection against symptom- 
matic uncomplicated malaria (7). However, 
inconsistencies exist regarding whether or not 
the SCT protects against asymptomatic mala- 
rial parasitemia (AMP) in tropical populations. 
While some studies (7,14) suggested that SCT 
was protective and associated with low preva- 
lence of AMP, other studies (7,15) found no 
such protective association between SCT and 
AMP in tropical populations. These inconsis- 
tencies call for further studies. Surprisingly, to 
the best of our knowledge, the effect of Hb-
phenotypes on the prevalence of AMP has not 
been explored among blood donors in Nigeria 
or other malaria-endemic countries, where 
transfusion safety is low and the risk of 
transfusion transmitted malaria (TTM) is high 
(16,17). We therefore intended to study the 
effect of Hb phenotypes (SCT versus HbAA) on 
the prevalence and risk of AMP among appa- 
rently healthy blood donors in Nigeria.  
 As in many other tropical countries, 
donor screening for AMP and post transfusion 
haemovigilance of patients are not routinely 
conducted in Nigeria, hence the exact incidence 
of TTM among transfused patients in Nigeria is 
unknown (18,19). However, the incidence of 
TTM is presumably high because the preva- 
lence of AMP among Nigerian donors was 
reported to range from 6% to as high as 
45.8% (16,17). Nonetheless, we predicted that 
SCT would protect donors against AMP, while 
HbAA would increase donors’ susceptibility to 
AMP. We thus hypothesized that SCT and HbAA 
would be associated with low and high risks of 
AMP among blood donors respectively. If our 
prediction and hypothesis are correct, AMP 
positive blood donors will have significantly 
lower relative frequencies of SCT and higher 
relative frequencies of HbAA phenotypes in 
  
Materials and method: 
  
Study setting and design 
 This is a ‘case-control’ study with a 
total of 200 apparently healthy blood donors; 
100 with AMP (as case) and 100 without AMP 
(as control). The study was conducted to 
investigate the risk of AMP with respect to Hb 
phenotypes (SCT versus HbAA) and carried out 
during the year 2017 at Rasheed Shekoni 
Teaching Hospital, Dutse, North-West Nigeria, 
and Federal Medical Centre, Birnin Kudu, 
North-West Nigeria. The study was conducted 
after obtaining informed consent of the donors 
and approval of the ethical committees of the 
hospital. 
 
Subject participants, inclusion and exclusion 
criteria 
 Apparently healthy donors who passed 
the pre-donation clinical evaluation and Hb 
estimation, and tested negative for infectivity 
markers of hepatitis B and C, HIV and syphilis 
were consecutively recruited at the time of 
blood donation in the blood bank of the study 
hospital. Prospective donors who failed any of 
the aforementioned pre-donation assessments 
were excluded from this study.  
 
Microscopic evaluation and speciation of AMP 
 All recruited donors were investigated 
for AMP by manual technique based on micro- 
scopic examination of Giemsa-stained thick 
blood smears and Leishman-stained thin blood 
smears using standard techniques (22). If no 
parasite was found in 100 oil‑immersion micro- 
scopic fields of a thick smear, the sample was 
considered negative for malaria parasite (22). 
Samples positive for malaria parasite by thick 
smear were further tested by thin smear for 
morphological identification of parasite species, 




while parasite density was microscopically 
estimated on the thick smear by counting the 
number of asexual forms of the parasites per 
high power field (HPF) (22). Parasites density 
levels were documented by using the plus (+) 
grading system (22); count of 1-10 parasites 
per 100 HPF = (1+), 11-100 parasites per 100 
HPF = (2+), 1-10 in single HPF = (3+), and 
>10 parasites in single HPF = (4+) (22).  
significant.     
 The risks of AMP associated with SCT 
and HbAA were calculated as Odds ratios (OR) 
and separately determined by age and gender 
adjusted case-control logistic regression 
analysis using the following inputs; OR for the 
risk of AMP associated with SCT = number of 
cases with SCT/number of cases with HbAA) / 
(number of controls with SCT/number of 
controls with HbAA), and OR for the risk of AMP 
associated with HbAA = number of cases with 
HbAA/number of cases with SCT) / (number of 
controls with HbAA/number of controls with 
SCT). A ‘low risk OR’ (i. e. OR<1) was consi- 
dered to be statistically significant if the upper 
limit of 95% confidence interval (95% CI) was 
less than 1.0 with p<0.05; and a ‘high risk OR’ 
(i. e. OR>1) was considered to be statistically 
significant if the lower limit of the 95% CI was 
greater than 1.0, with p<0.05. An OR was 
considered statistically insignificant if the range 
of its 95% CI included 1.0, with p>0.05.  
 
Donor categorization on the basis of micro- 
scopy results for AMP 
 Donors with AMP (n=100) were cate- 
gorized as ‘case’. Equal number of subjects 
were randomly selected from donors without 
AMP (n=100) to serve as ‘control’. 
 
Determination of ABO blood groups 
 The ABO blood groups were determined 
by standard manual techniques using mono- 
clonal anti-A and anti-B against donors’ red 
cells in saline tubes at room temperature, and 
read for agglutination after 15 min incubation. 
On the basis of the pattern of agglutination, 
donor red cells were categorized as group O, A, 




Determination of Hb phenotypes  
 All of the 100 donors with AMP had low 
parasite density level of (1+), and the parasite 
morphology was consistent with P. falciparum 
in all cases. The distribution of donor age, 
gender and relative frequencies of Hb pheno- 
types and ABO blood groups among donors 
with AMP and control donors are shown in 
Table 1. There were no significant differences 
between them with respect to mean age (28.5 
years vs. 27.7 years, p>0.05), gender (male; 
98% vs 97%, p>0.05 and female; 2% vs 3%, 
p>0.05), relative frequencies of blood group-O 
(51% vs 53%, p>0.05), and non-O blood 
groups (49% vs 47%, p>0.05).  
 However, the relative frequencies of Hb 
phenotypes revealed that donors with AMP had 
significantly lower frequencies of SCT (12% vs 
28%, p<0.05) and higher frequencies of HbAA 
(88% vs 72%, p<0.05) compared to control 
donors. The Odd Ratios for the risk of AMP with 
respect to donor Hb phenotypes are shown in 
Table 2, wherein HbAA is associated with a 
high OR of 2.91 (95% CI: 2.10-3.48, p= 
0.021), while SCT is associated low OR of 0.49 
(95% CI: 0.27-0.73, p=0.032). 
 The Hb phenotypes were determined 
by Hb electrophoresis at a pH of 8.6 on cellu- 
lose acetate paper. On the basis of electro- 
phoretic patterns, the Hb phenotypes were 




 Statistical analyses of data were 
performed using the Statistical Package for the 
Social Sciences (SPSS) software version 15.0 
(SPSS Inc., Chicago, IL, USA). Frequency 
distribution of ABO blood groups and Hb 
phenotypes among study donors study cohort 
were presented as percentages. Age of study 
donors study cohort was calculated in years 
and presented as mean and standard 
deviation, while gender profile of the study 
donors study cohort was presented as 
proportions (percentages) of male and female 
donors. Mean values of data were compared 
between case donors (with AMP) and control 
donors (without AMP) by Student’s t-test and 
proportions (percentages) by Χ2-test.  P value 
less than 0.05 was considered statistically 
 
  




Table1: Age, gender, ABO groups, and Hb phenotypes among blood donors with AMP and control blood donors 
 
Parameters No of donors with AMP (%) 
(n=100) 
No of donors without 
AMP (control donors) 
(%) (n=100) 
p value 
Mean age (years) (± SD) 28.5±3.2 27.7±2.3 >0.05 
Male  98 (98) 97 (97) >0.05 
Female  2 (2) 3 (3) >0.05 
Blood group-O 51 (51) 53 (53) >0.05 
 Blood non-O groups [A+B+AB] 49 (49) 47 (47) >0.05 
HbAA  88 (88) 72 (72) <0.05 
SCT 12 (12) 28 (28) <0.05 
AMP: Asymptomatic Malarial Parasitemia. SCT: Sickle Cell Trait (HbAS) 
  
 
Table 2: Odds ratios (OR) for the risk of AMP with respect to donor Hb phenotypes 
 
Hb phenotypes No of donors 
with AMP 
(%) (n=100) 





OR values  
(95% CI) 
P value Inference 
HbAA 88 (88) 72 (72) 2.91 (2.10-3.48) 0.021 HbAA is associated 
with high risk of AMP 
in blood donors 
SCT 12 (12) 28 (28) 0.49 (0.27-0.73) 0.032 SCT is associated with 
low risk of AMP in 
blood donors 
AMP: Asymptomatic Malarial Parasitemia. SCT: Sickle Cell Trait (HbAS) 
 
 
Discussion: the developed countries (26). In addition, 
younger people are relatively more educated 
(26), and are therefore more amenable to 
donor recruitment campaigns. The overwhelm- 
ming preponderance of male donors as seen in 
this study is a reflection of the general low 
level of blood donation among the female 
population in Nigeria (27). Despite the fact that 
blood donation is acceptable from healthy 
females that are not pregnant or breast feeding 
(9), there is a misconception in the general 
Nigerian population that women are not eligible 
to donate blood (27). There is therefore the 
need to rectify this misconception by re-confi- 
guring our donor mobilization strategy in order 
to target and sensitize the female sector (28), 
which constitutes about half of the Nigerian 
population (26). Lack of significant differences 
in donor age, gender and ABO blood group 
distributions between donors with AMP and 
control donors suggested that these para- 
meters did not affect the risk of AMP among 
the blood donors studied in this study, which is 
consistent with the findings of previous studies 
(17). However, we found striking and signifi- 
cant differences between donors with AMP and 
control donors with respect to the distribution 
of Hb phenotypes among the study population.  
 
 With the largest back population of 
over 200 million, SCT frequency of 25-30% and 
SCD prevalence of 1-3%, Nigeria carries the 
heaviest burden of the sickle cell gene in the 
world (20). Moreover, malaria is endemic in 
Nigeria, which has a year-round transmission 
with up to 97% of the population being at risk 
of malaria infection (21). Thus, virtually the 
entire Nigerian population is at risk of malaria 
infection, which is predominantly caused by P 
falciparum specie (21). Inspite of the fact that 
the prevalence rates of SCT and AMP are high 
in Nigeria (12,13,16,17), and despite the WHO 
recommendation that countries with high pre- 
valence of SCT and malaria infection should 
screen their donors (9), Nigerian blood banks 
do not routinely screen prospective donors for 
SCT or AMP. Therefore, both SCT and AMP are 
prevalent among apparently healthy blood 
donors in Nigeria.   
 Nigerian blood donor panels are predo- 
minated by young people as revealed by the 
donor mean ages of less than 30years reported 
in this study. This is consistent with the demo- 
graphic profiles of Nigerian blood donors as 
reported in previous studies (25). This pattern 
is a manifestation of the demographic structure 
of Nigeria, which is a developing country with a 
relatively young population in comparison to 
 The distribution of Hb phenotypes 
among our control donors (without AMP) 
revealed that HbAA and SCT occurred with 




relative frequencies of 72% and 28% respec- 
tively, which is consistent with the relative 
frequencies of Hb phenotypes in the general 
population in Nigeria (20). In contrast, donors 
with AMP showed a distorted distribution of Hb 
phenotypes with significantly higher relative 
frequency of HbAA (88%) and lower relative 
frequency of SCT (12%). Logistic regression 
analysis of the differences in the relative 
frequencies of Hb phenotypes vis-à-vis the risk 
of AMP among blood donors revealed OR of 
2.91 and 0.45 for HbAA and SCT respectively. 
These ORs suggested that donors with HbAA 
were about 3 times more likely to have AMP 
than control donors, while donors with SCT 
were about 50% less likely to have AMP than 
control donors. Therefore, the two ORs implied 
that HbAA was associated with high risk of 
AMP, while SCT was associated (and pro- 
tective) with low risk of AMP among blood 
donors.     
 Our findings are at variance with pre- 
vious studies, which reported that SCT did not 
protect against AMP (7,15). However, our 
findings are consistent with our working hypo- 
thesis, and are in conformity with previous 
studies, which reported that SCT protected 
against AMP (7,14). Moreover, these findings 
are in keeping with the fact that persons with 
SCT resist malaria infection through innate, 
immunological and biochemical mechanisms, 
which include reduced red cell invasion by the 
parasite, low intra-red cell parasite prolife- 
ration, parasite-induced red cell sickling and 
phagocytosis, reduced rosetting and cyto- 
adherence of parasitized red cells, and enh- 
anced cellular and humoral immune response 
against the malaria parasite (7). 
pregnant women, neonates and children, and 
patients with cancers, HIV/AIDS and SCD (29). 
However, two categories of patients (neonates 
and SCD patients) deserve careful conside- 
ration because in addition to their individual 
vulnerabilities, they are selectively transfused 
with HbAA blood, which we found (in this 
study) to be associated with high risk of AMP 
and by implication, high risk of TTM. 
  Nigeria has one of the highest birth 
rates in the world (26), with a commensurate 
high frequency of neonatal anaemia, jaundice 
and transfusion due to high prevalence of 
sepsis, prematurity, and G6PD-deficiency (30). 
The standard of care for best practice for 
neonatal transfusion requires selective use of 
HbAA blood (9,31), which unfortunately is 
associated with high risks of AMP and TTM as 
seen in this study. It is well known that 
neonates are naturally protected from malaria 
by two barriers viz maternal antibodies and 
HbF (32,33). Nevertheless, these neonatal 
protective barriers can be easily overcome by 
direct transfusion of malaria infected blood for 
four reasons. First, neonates are selectively 
transfused with HbAA, which carries higher risk 
of AMP as found in this study. Second, neo- 
nates are often transfused with fresh blood 
(31), and malaria parasites remain viable in 
stored refrigerated blood for only about two 
weeks (34), hence fresh blood is more likely to 
transmit malaria than old stored blood (19). 
Third, relative to the size of the neonate, the 
parasite dose in infected donor blood is often 
massive, and it has been suggested that a 
massive infective dose would easily overwhelm 
the protective barriers and lead to the esta- 
blishment of malaria (35). Fourth, neonatal 
transfusions are often given by exchange blood 
transfusion (EBT) procedures (30), and EBT 
invariably removes the protective maternal 
antibodies (32) and HbF (33) in the discarded 
neonatal blood. For the reasons above, TTM is 
an important complication of neonatal trans- 
fusion in Nigeria and other malaria endemic 
countries (36). Therefore, neonates that are 
transfused must be closely monitored for any 
clinical manifestations of TTM.  
 The result of our study has triple 
clinical implications with respect to the risk of 
TTM in the practice of transfusion medicine in 
the tropics. First, the results suggest that blood 
donated by persons with HbAA is associated 
high risk of TTM. Second, blood donated by 
persons with SCT is associated with low risk of 
TTM, hence we believe that donor SCT is an 
important but surreptitious mitigator of the risk 
of TTM in the tropics. Third, patients who are 
selectively transfused with HbAA blood would 
be at increased risk of acquiring TTM. Suffices 
to say that TTM is a serious but inadequately 
quantified (i. e. exact incidence is unknown due 
to lack of post transfusion haemovigilance) 
complication of blood transfusion in Nigeria and 
other malaria endemic countries (18,19). 
Nonetheless, the risk of acquiring TTM would 
certainly be higher among patients with various 
forms of vulnerabilities and immune incom- 
petence as may be encountered in the elderly, 
 Nigeria carries the heaviest burden of 
SCD in the world (20). The management of 
SCD is transfusion intensive (37), and in simi- 
larity with neonatal transfusion, the standard of 
care for best practice for SCD transfusion 
requires selective use of HbAA blood (9,38). 
Although SCD patients are fundamentally vul- 
nerable to malaria by virtue of their immune 
compromised status (39), we believe that the 
selective transfusion of HbAA blood would 
increase their risks of acquiring TTM. 




Consequently, TTM is an important compli- 
cation seen among SCD patients who had 
received blood transfusion from donors within 
or originating from malaria endemic countries 
(40,41). Therefore, SCD patients and their 
parents should be adequately counseled to 
strictly comply with their routine anti-malarial 
chemo-prophylaxis as is usually incorporated in 
the standard of care for SCD patients who are 
resident in their native malaria-endemic tro- 
pical countries (42). Nonetheless, SCD patients 
who are transfused must be closely monitored 
for any clinical manifestations of TTM. 
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